Esophageal Adenocarcinoma

Nationwide Dutch Study Reveals Limited Prior Endoscopic Surveillance in Barrett’s Esophagus-Related Dysplasia and Cancer Diagnosis

By MedXY 09/26/2026

In a large Dutch cohort, 90% of patients with Barrett’s esophagus-related dysplasia or cancer had no prior endoscopic surveillance, highlighting a critical gap in early detection and the need for evidence-based screening strategies.

Gastroenterology news Oncology

Achalasia and Its Differential Impact on Esophageal Squamous Cell Carcinoma and Adenocarcinoma Risk: Insights from a Large Nordic Case-Control Study

By MedXY 09/05/2026

A comprehensive multinational study reveals that achalasia significantly raises the risk of esophageal squamous cell carcinoma independently, while its association with adenocarcinoma is modest and largely mediated by gastroesophageal reflux disease.

Gastroenterology news Oncology

Comparing FLOT and CROSS Protocols: Survival and Recurrence in Esophageal Adenocarcinoma with Pathological Complete Response

By MedXY 07/24/2026

This cohort study compares long-term survival and recurrence in esophageal adenocarcinoma patients achieving pathological complete response (pCR) after neoadjuvant FLOT chemotherapy versus CROSS chemoradiotherapy, highlighting better outcomes with FLOT.

Clinical Updates news Oncology

Therapeutic Reversal of SOX9-Mediated Chemoresistance in Esophageal Adenocarcinoma via APE1-Redox Inhibition

By MedXY 03/15/2026

This review details a breakthrough in esophageal adenocarcinoma treatment, identifying the APE1-SOX9 axis as a primary driver of chemoresistance and demonstrating how targeting APE1's redox function can sensitize tumors to oxaliplatin.